Overview

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
This study will treat subjects with complicated VVC who have failed prior fluconazole therapy with Ibrexafungerp for 1, 3 or 7 days of treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Scynexis, Inc.
Treatments:
Ibrexafungerp